- General Drug Summary
- Drug Name
- Chenodeoxycholic acid
- Description
- Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones. It can also reduce the amount of other bile acids that can be harmful to liver cells when levels are elevated.
- Also Known As
- Chenocholic acid; Chenodesoxycholic acid; Chenodiol
- Categories
- Cholagogues and Chol
- Structure
- Summary In Neonatal Jaundice
-
1 record(s) for Chenodeoxycholic acid Adverse Event in Neonatal Jaundice.
- PMID
- Drug Name
- Efficacy
- Evidence
- 6176451
- Chenodeoxycholic acid
- Adverse Event
- Clinical Trial
- Summary
- Be indicated for patients with slight cholestasis.
- Cholic acid, chenodeoxycholic acid, alpha-1-fetoprotein and alpha-1-antitrypsin serum concentrations in breast-fed infants with prolonged jaundice. European journal of pediatrics, 1982 Feb [Go to PubMed]
- Thirteen breast-fed one-month-old infants with prolonged jaundice not due to known causes were included in this study. All infants were investigated at one and twelve months of age. Serum concentrations of total (TB) and conjugated bilirubin (CB), aspartate (ASAT) and alanine aminotransferase (ALAT), alkaline phosphatase (AP), alpha-1-antitrypsin (alpha-1-AT), alpha-1-fetoprotein (AFP) and the two primary bile acids; cholic (CA) and chenodeoxycholic acid (CDCA) were determined at both ages. The Pi-phenotype of alpha-1-AT was determined at the age of twelve months. The serum concentrations of TB, CB, AP and AFP were elevated at the age of one month but were normal at the age of twelve months. No changes in the serum concentrations of ASAT or ALAT were observed between one and twelve months of age, and the values were within the reference ranges. The serum concentrations of alpha-1-AT were within the reference range at both ages. Two infants were heterozygous for MZ, and they had normal serum alpha-1-AT concenrations. The serum concentrations of CA and CDCA were elevated at the age of one month and were still significantly elevated at the age of twelve months indicating that the infants had slight cholestasis at the age of one month, and that the cholestasis had largely subsided by the end of the first year of life.
-
1 record(s) for Chenodeoxycholic acid Effective in Inducing Remission in Neonatal Jaundice.
- PMID
- Drug Name
- Efficacy
- Evidence
- 7317547
- Chenodeoxycholic acid
- Effective in Inducing Remission
- Clinical Trial
- Summary
- Concentrations of Chenodeoxycholic acid has value in assessing the severity or prognosis of Neonatal hyperbilirubinemia.
- Serum cholic acid and chenodeoxycholic acid concentrations in neonatal hyperbilirubinemia. Biology of the neonate, 1981 [Go to PubMed]
- Primary bile acid concentrations were measured in serum of 332 newborns with neonatal hyperbilirubinemia (serum total bilirubin level greater than 200 mumol/l) and compared with those of 95 nonhyperbilirubinemic neonates (serum total bilirubin level less than 200 mumol/l). The serum concentrations (mumol/l; mean +/- SEM) for cholic acid (8.78 +/- 0.44) and chenodeoxycholic acid (10.5 +/- 0.68) were significantly higher (p less than 0.001) in the hyperbilirubinemic group than in the controls (7.16 +/- 0.48 and 6.67 +/- 0.48, respectively). 80 (24%) of the hyperbilirubinemic newborns had true cholestasis (serum levels of cholic and/or chenodeoxycholic acid higher than mean +/- 2 SD in the reference group). The ratio of cholic to chenodeoxycholic acid was significantly higher (p less than 0.05) in the cholestatic group than in the hyperbilirubinemic newborns without cholestasis. There was no significant differences in the serum concentrations of alkaline phosphatase or lactate dehydrogenase between the cholestaic and noncholestatic groups. In the hyperbilirubinemic newborns, the primary bile acids were indiscriminately raised. Only 8 infants from the 332 newborns had jaundice at the age of 1 month. Of these 8 infants only 2 had neonatal cholestatic hyperbilirubinemia. It thus appears that measurement of serum primary bile acid concentrations has only limited diagnostic value in assessing the severity or prognosis of neonatal hyperbilirubinemia.
-
1 record(s) for Chenodeoxycholic acid Effective in Complication in Neonatal Jaundice.
- PMID
- Drug Name
- Efficacy
- Evidence
- 1583874
- Chenodeoxycholic acid
- Effective in Complication
- Case Report
- Summary
- 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency treat with chenodeoxycholic acid led to clinical and biochemical improvement. prolonged Neonatal jaundice followed by symptoms of malabsorption of fat-soluble vitamins.
- 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase deficiency; effect of chenodeoxycholic acid therapy on liver histology. Journal of inherited metabolic disease, 1992 [Go to PubMed]
- The second step in the pathway for synthesis of bile acids from cholesterol is catalysed by the enzyme 3 beta-hydroxy-delta 5-C27-steroid dehydrogenase. Deficiency of this enzyme has been reported to produce cholestatic liver disease with progressive cirrhosis. Treatment with chenodeoxycholic acid led to clinical and biochemical improvement in one patient. We report a further child with this disorder who presented with prolonged neonatal jaundice followed by symptoms of malabsorption of fat-soluble vitamins. Bile acid replacement therapy resulted in clinical and biochemical improvement; it was also possible to demonstrate improvement in the histological appearance of the liver biopsy 4 months after commencing treatment.
-
1 record(s) for Chenodeoxycholic acid Effective in Basic Research in Neonatal Jaundice.
- PMID
- Drug Name
- Efficacy
- Evidence
- 6707843
- Chenodeoxycholic acid
- Effective in Basic Research
- Review
- Summary
- Concentrations of Chenodeoxycholic acid has value in assessing the severity or prognosis of Neonatal hyperbilirubinemia.
- Effect of phototherapy on the physiologic cholestasis of the neonate. Journal of pediatric gastroenterology and nutritio, 1984 Mar [Go to PubMed]
- Phototherapy (PT) has been reported to increase bile acid excretion in the bile of adults with liver cirrhosis. We investigated the effect of PT on the levels of serum total bile acids (STBA), conjugated cholic acid (CCA), conjugated chenodeoxycholic acid (CCDCA), conjugated lithocholic acid (CLCA), and sulfolithocholylglycine (SLCG) in 13 neonates with unconjugated nonhemolytic hyperbilirubinemia before and after 12 h of PT. The treatment produced a statistically significant (p less than 0.02) reduction in both STBA and CCA levels, whereas no effect on the other fractions was observed. The percentage of reduction was the same for STBA and CCA concentrations, indicating that the effect is related to a specific reduction in CCA levels. The magnitude of the expected decrease in the level of serum bilirubin is not correlated with that in bile acids in individual cases. The data are interpreted as suggesting that PT can affect the metabolism of bile acids by decreasing STBA and CCA levels in neonates through an ncrease in their biliary excretion associated with the reduced intestinal absorption of CCA occurring in newborns.